$AVNS

Pacitti David sold (to issuer) $19.2M of AVNS

Pacitti David (Chief Executive Officer) sold (to issuer) 766,924 shares of AVANOS MEDICAL, INC. (AVNS) at $25.00 ($19.17M total) across 2 trades on 2026-07-27.

Original reporting
SEC EDGAR · Pacitti David
Published Jul 28, 2026, 9:39 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 28, 2026, 9:40 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AVNS
Neutral
medium confidence
Mentioned
$AVNS
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVNSNeutralLow
01

Why it matters

The CEO sold a large block at a fixed price and reports 0 shares after the transaction, which may influence short-term sentiment but lacks any new fundamental information in the text.

02

Market read

Traders may monitor for follow-on insider activity or interpret the full exit as sentiment signal, but the filing alone does not change the company’s fundamentals.

03

What to watch

The filing does not state whether the sale was part of a structured program or buyback mechanics beyond the D code, and it provides no accompanying company performance or guidance changes.

Relevance 7/10Novelty 3/10Timing: filed after-hours on 2026-07-28, covering trades dated 2026-07-27

Background

The article is an SEC Form 4 insider transaction disclosure for AVANOS MEDICAL, INC. (AVNS).

Company-level read

Ticker impact

$AVNSNeutralMedium confidence
Context

CEO Pacitti David sold 766,924 shares to the issuer at $25.00/share, leaving 0 shares after the transaction.

Expected impact

Likely limited near-term impact; could slightly weigh on sentiment if traders interpret it as reduced insider confidence, but buyback-participation codes often mute that signal.

Evidence & confidence

The filing is a Form 4 insider transaction with a D code (sale to issuer) and the CEO ends with 0 shares, but the text provides no earnings, guidance, or operational catalyst.

Market effects

No sector-level implications disclosed; this is company-specific insider transaction reporting.

None indicated.

None indicated.

Counterpoint

The D code suggests a sale to the issuer, which can reflect routine buyback participation or liquidity planning rather than a bearish view on fundamentals.

Key entities

  • AVANOS MEDICAL, INC.

    Company whose CEO insider sale to issuer is disclosed via Form 4.

  • Pacitti David

    Chief Executive Officer who sold 766,924 shares to the issuer at $25.00/share.

Related articles

$AVNSLow

AVANOS MEDICAL, INC. (AVNS): Completion of Acquisition or Disposition of Assets

AVANOS MEDICAL, INC. (AVNS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-10.1 4 avnsform8k_07272026xex101.htm EX-10.1 Document Execution Version CREDIT AGREEMENT dated as of July 27, 2026 among A-AV MERGERSUB, INC., as the Initial Borrower, AVANOS MEDICAL, INC., as the Borrower Representative, A-AV ACQUIRECO, INC., as a Borrower, A-AV INTERMEDIATEC